LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 9 of 15: Cell count and normalized growth rate inhibition values within biological replicate 2. - Dataset - HMS LINCS Database

LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 9 of 15: Cell count and normalized growth rate inhibition values within biological replicate 2. - Dataset (ID:20246)

Download: Excel (XLSX), Comma-separated (CSV)

<<<<

Select the entities to show:

Small molecules	Cells

|<
<<
Previous
Page 310 of 520
Next
>>
>
7726 to 7750 of 12982 records
per page:

Cell	Small Molecule	Small Mol Concentration	Small Mol Conc Unit	LJP Library Plate	Replicate	Assay Well	Timepoint	Timepoint Unit	Total Cell Count Before Treatment	Total Cell Count After Treatment	Total Control Cell Count	Relative Cell Count	Normalized Growth Rate Inhibition Value
BT-20	PI103	10	uM	LJP6	3	I13	72	hr	1334	1007	3921	0.2568	-0.1657
BT-20	Dovitinib	0.04	uM	LJP5	1	E24	72	hr	1334	3107	3930	0.7904	0.7198
BT-20	Dovitinib	0.04	uM	LJP5	2	E24	72	hr	1334	3721	4051	0.9185	0.8967
BT-20	Dovitinib	0.04	uM	LJP5	3	E24	72	hr	1334	3357	4117	0.8153	0.7638
BT-20	Dovitinib	0.12	uM	LJP5	1	E23	72	hr	1334	3228	3930	0.8212	0.7625
BT-20	Dovitinib	0.12	uM	LJP5	2	E23	72	hr	1334	3357	4051	0.8287	0.7786
BT-20	Dovitinib	0.12	uM	LJP5	3	E23	72	hr	1334	3728	4117	0.9054	0.8813
BT-20	Dovitinib	0.37	uM	LJP5	1	E22	72	hr	1334	2461	3930	0.6261	0.4809
BT-20	Dovitinib	0.37	uM	LJP5	2	E22	72	hr	1334	2399	4051	0.5922	0.4420
BT-20	Dovitinib	0.37	uM	LJP5	3	E22	72	hr	1334	2789	4117	0.6773	0.5737
BT-20	Dovitinib	1.11	uM	LJP5	1	E21	72	hr	1334	1961	3930	0.4989	0.2801
BT-20	Dovitinib	1.11	uM	LJP5	2	E21	72	hr	1334	2152	4051	0.5312	0.3475
BT-20	Dovitinib	1.11	uM	LJP5	3	E21	72	hr	1334	2194	4117	0.5328	0.3577
BT-20	Dovitinib	3.33	uM	LJP5	1	E20	72	hr	1334	1793	3930	0.4561	0.2086
BT-20	Dovitinib	3.33	uM	LJP5	2	E20	72	hr	1334	1752	4051	0.4325	0.1851
BT-20	Dovitinib	3.33	uM	LJP5	3	E20	72	hr	1334	1904	4117	0.4624	0.2443
BT-20	Dovitinib	10	uM	LJP5	1	E19	72	hr	1334	1477	3930	0.3758	0.0672
BT-20	Dovitinib	10	uM	LJP5	2	E19	72	hr	1334	1503	4051	0.3710	0.0770
BT-20	Dovitinib	10	uM	LJP5	3	E19	72	hr	1334	1405	4117	0.3412	0.0321
BT-20	GSK 690693	0.04	uM	LJP5	1	F24	72	hr	1334	3208	3930	0.8161	0.7555
BT-20	GSK 690693	0.04	uM	LJP5	2	F24	72	hr	1334	3508	4051	0.8659	0.8281
BT-20	GSK 690693	0.04	uM	LJP5	3	F24	72	hr	1334	3640	4117	0.8840	0.8539
BT-20	GSK 690693	0.12	uM	LJP5	1	F23	72	hr	1334	3091	3930	0.7864	0.7142
BT-20	GSK 690693	0.12	uM	LJP5	2	F23	72	hr	1334	3814	4051	0.9415	0.9261
BT-20	GSK 690693	0.12	uM	LJP5	3	F23	72	hr	1334	3682	4117	0.8942	0.8670

|<
<<
Previous
Page 310 of 520
Next
>>
>
7726 to 7750 of 12982 records
per page:

HMS LINCS Project

LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 9 of 15: Cell count and normalized growth rate inhibition values within biological replicate 2. - Dataset (ID:20246)